Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11364289
APP PUB NO 20200030424A1
SERIAL NO

16600064

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Embodiments herein relate to humanized CD19 antibodies and disease treatment using the antibodies. For example, a subject having a CD19 positive tumor may be administered a therapeutically effective amount of the humanized antibody.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS LTDGEORGE TOWN

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cao, Zhiyuan Shanghai, CN 48 112
Liu, Zhigang Shanghai, CN 101 1402
Pu, Chengfei Shanghai, CN 48 108
Wu, Zhao Shanghai, CN 94 260
Xiao, Lei Shanghai, CN 180 647

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Dec 21, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 21, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 21, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00